Home > Srdan Verstovsek, ASH 2019: Individualized Management of Myeloproliferative neoplasms
Haematology

Srdan Verstovsek, ASH 2019: Individualized Management of Myeloproliferative neoplasms

Published Online: December 18th 2019

At the 61st ASH Annual Meeting & Exposition, Srdan Verstovsek, Anderson Cancer Center, discusses his presentation on Approaches to the Individualized Management of Myeloproliferative Neoplasms: Best Practices and Guidance to Optimize Care.

Questions

1. What impact has molecular profiling had on the prognostication and treatment of myeloproliferative neoplasms (MPNs)? (0:05)

2. What is the rationale for risk-adapted therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV)? (1:47)

3. What are the most important emerging therapies for MPNs? (3:12)

4. What factors should be considered when selecting the most appropriate treatment for an individual? (4:43)

5. How can we best manage treatment-related toxicities and optimise dosing regimens? (6:24)

 

Srdan Verstovsek has no conflicts of interest to declare in relation to this video.

Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.

Related Videos In Haematology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar